Cardiol Therapeutics Announces Topline Results From the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - PressReach

Cardiol Therapeutics’ stock down 20% on Phase II CardiolRx failure

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.The post Cardiol Therapeutics’ stock down 20% on Phase II CardiolRx failure appeared first on Clinical Trials Arena.

Cardiol Therapeutics’ Cannabidiol Formulation Reduced Inflammation—Phase II Topline Data Ignites the Race to Treat Acute Myocarditis

A single‐digit p-value has rarely carried such freight. Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) this morning unveiled topline data from its Phase II ARCHER trial showing that its oral cannabidiol formulation CardiolRx™ showed a notable improvement in left-ventricular (LV) extracellular volume (ECV) — a magnetic-resonance proxy for myocardial edema and scarring — just enough to flirt with statistical significance (p = 0.0538) versus …

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - PressReach

Open the article to view the coverage from pressreach.com

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Open the article to view the coverage from Investing News Network